Cytek Biosciences (CTKB) Non Operating Income (2020 - 2026)

Cytek Biosciences has reported Non Operating Income for 7 years, with the latest figure at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 70.61% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $8.3 million (down 56.39% YoY), and the FY2025 full-year result was $10.5 million, down 28.87% from the prior year.
• Non Operating Income for Q1 2026 stood at $1.1 million, down from $2.0 million in the prior quarter.
• The five-year high for Non Operating Income was $10.9 million in Q4 2024, with the low at -$946000.0 in Q1 2022.
• Historically, Non Operating Income has averaged $2.4 million across 5 years, with a median of $1.7 million in 2023.
• Annual changes were most pronounced in 2022 — Non Operating Income tumbled 325.0% — and 2023, when it surged 441.18%.
• Cytek Biosciences' Non Operating Income stood at $4.0 million in 2022, then gained by 5.41% to $4.2 million in 2023, then surged by 155.44% to $10.9 million in 2024, then tumbled by 81.57% to $2.0 million in 2025, then slumped by 45.5% to $1.1 million in 2026.
• The last three Non Operating Income figures came in at $1.1 million (Q1 2026), $2.0 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.